Literature DB >> 1600600

Toxicity and metabolism of 3'-deoxyadenosine N1-oxide in mice and Ehrlich ascites tumor cells.

K R Svendsen1, K Overgaard-Hansen, S Frederiksen, S A Engelholm, N T Pedersen, L L Vindeløv.   

Abstract

The toxic effect of 3'-deoxyadenosine N1-oxide (3'-dANO) on mice, on their different organs, and on Ehrlich ascites tumor cells was studied. In both healthy and tumour-bearing animals, the lethal dose for 10% of the mice receiving i.p. injections (LD10) of 3'-dANO was estimated to be about 300 mg/kg x 4 days in one mouse strain (Theiller). In another mouse strain (NMRI), we obtained a markedly higher LD10 value (675 mg/kg x 5 days). At nonlethal doses (250 mg/kg x 4 days), we observed reversible neurological symptoms on days 4-12 after treatment, but no macroscopical or microscopical changes was detected in the brain, heart, thymus, lung, lymph node, spleen, liver, kidney, bone marrow, or gastrointestinal tract. At doses of 450 mg/kg x 4 days, severe neurological symptoms were observed, and atony of the gastrointestinal canal and damage to the kidney and liver were registered. Even at doses that were lethal to the mice, no histopathological change was observed in the bone marrow or in the gastrointestinal canal. Pharmacokinetics studies showed that after the i.p. injection of 3'-dANO, the maximal plasma concentration was reached after 10 min, after which it declined showing a half-life of about 40 min. A transient accumulation of 3'-deoxyadenosine triphosphate (3'-dATP) was observed within 24 h in the liver and kidney, with the maximal concentration being reached after about 2-3 h. 3'-dANO was excreted partly as the unchanged substance and partly as the metabolite 3'-deoxyinosine within 24 h. Flow-cytometric DNA analysis of Ehrlich tumor cells treated either in vitro or in vivo with 3'-dANO revealed no therapy-induced change in the cell-cycle perturbations, which indicates that cells were randomly killed during all phases of the cycle.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1600600     DOI: 10.1007/bf00686398

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  41 in total

1.  Adenosine deaminase from human erythrocytes: purification and effects of adenosine analogs.

Authors:  R P Agarwal; S M Sagar; R E Parks
Journal:  Biochem Pharmacol       Date:  1975-03-15       Impact factor: 5.858

2.  Differential spectrophotometry of purine compounds by means of specific enzymes; determination of adenine compounds.

Authors:  H M KALCKAR
Journal:  J Biol Chem       Date:  1947-02       Impact factor: 5.157

3.  Some properties of partially purified mammalian adenosine kinase.

Authors:  B Lindberg; H Klenow; K Hansen
Journal:  J Biol Chem       Date:  1967-02-10       Impact factor: 5.157

Review 4.  Modulation of neurotransmission by purine nucleotides and nucleosides.

Authors:  B B Fredholm; P Hedqvist
Journal:  Biochem Pharmacol       Date:  1980-06-15       Impact factor: 5.858

5.  Autoradiographic localization of adenosine receptors in rat brain using [3H]cyclohexyladenosine.

Authors:  R R Goodman; S H Synder
Journal:  J Neurosci       Date:  1982-09       Impact factor: 6.167

6.  A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry.

Authors:  B T Hill; R D Whelan; H T Rupniak; L Y Dennis; M A Rosholt
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 7.  Basic and clinical aspects of adenosinergic neuromodulation.

Authors:  P J Marangos; J P Boulenger
Journal:  Neurosci Biobehav Rev       Date:  1985       Impact factor: 8.989

8.  Cordycepin inhibits induction of murine leukovirus production by 5-iodo-2'-deoxyuridine.

Authors:  A M Wu; R C Ting; M Paran; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1972-12       Impact factor: 11.205

9.  Studies on the mechanism of cytotoxicity of 3'-deoxyadenosine N1-oxide in different strains of Ehrlich ascites tumor cells.

Authors:  K R Svendsen; K Overgaard-Hansen; S Frederiksen; H Loft; S A Engelholm
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Lack of cross-resistance between cytosine arabinoside and a new halogenated nucleoside analogue, 2-bromo-2'-deoxyadenosine in human acute myeloid leukaemia cells.

Authors:  L B Pemble; M G Lihou; R L Blakley; G P Jamieson; P J Smith
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

View more
  1 in total

Review 1.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.